Antioxidative and Hypoglycemic Effect of Ta-ermi Extracts on Streptozotocin-Induced Diabetes

Siqun Jing1, Zhengmei Zhao2, Jinzi Wu3

  • 1Yingdong Food College, Shaoguan Unversity, Shaoguan, Guangdong 512005, People's Republic of China.

Abstract

Insights

Ta-ermi extracts show potential in managing diabetes by reducing oxidative stress and lowering blood glucose levels. Further research is needed to identify the specific active compounds responsible for these beneficial effects.

Area of Science:

  • Herbal Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Oxidative stress and hyperglycemia are key factors in diabetes mellitus pathogenesis.
  • Streptozotocin (STZ)-induced diabetes models are widely used to study anti-diabetic agents.
  • Ta-ermi extracts are being investigated for their potential therapeutic effects in diabetes.

Purpose of the Study:

  • To evaluate the antioxidant and anti-diabetic effects of Ta-ermi water and alcohol extracts.
  • To assess the impact of Ta-ermi extracts on oxidative stress markers in STZ-diabetic animal models.
  • To investigate the effects of Ta-ermi extracts on mitochondrial complex I function in diabetic rats.

Main Methods:

  • In vitro antioxidant assays using DPPH and ABTS free radical scavengers.
  • Evaluation of hypoglycemic effects in STZ-induced diabetic mice.
  • Assessment of mitochondrial complex I activity in STZ-diabetic rat tissues (pancreas, liver, lung, kidney).

Main Results:

  • Ta-ermi extracts demonstrated significant in vitro antioxidant activity and inhibited glucosidase and aldose reductase.
  • Both extracts attenuated hyperglycemia, improved insulin sensitivity, and enhanced glucose tolerance in STZ-diabetic mice.
  • Ta-ermi extracts reduced blood glucose in STZ-diabetic rats, inhibited pancreatic mitochondrial complex I, and enhanced hepatic mitochondrial complex I activity.

Conclusions:

  • Ta-ermi water and alcohol extracts possess significant antioxidant and anti-diabetic properties.
  • These extracts may serve as functional food ingredients for diabetes management.
  • Further studies are required to isolate and identify the specific bioactive compounds responsible for the observed effects.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
514
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
443
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
460
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
627